Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study.

Van Den Neste, Eric;Cazin, Bruno;Janssens, Ann;González-Barca, Eva;Campàs, Clara;et.al.
(2013) Cancer Chemotherapy and Pharmacology — Vol. 71, n° 3, p. 581-591 (2013)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 324.52 KB
Request a copy

Details

Authors
  • Van Den Neste, Eric
    Author
  • Cazin, Bruno
    Author
  • Janssens, Ann
    Author
  • González-Barca, Eva
    Author
  • Campàs, Clara
    Author
Show more
Abstract
A MTD of 210 mg/kg was established with single acadesine dose. Multiple dose administrations at the OBD were tested with an acceptable safety profile, showing that acadesine might be a valuable agent for the treatment of relapsed/refractory CLL patients.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Van Den Neste, E., Cazin, B., Janssens, A., González-Barca, E., Terol, M. J., Levy, V., Pérez de Oteyza, J., Zachee, P., Saunders, A., de Frias, M., & Campàs, C. (2013). Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study. Cancer Chemotherapy and Pharmacology, 71(3), 581-591. https://doi.org/10.1007/s00280-012-2033-5 (Original work published 2013)